Free Delivery for Orders Above Ksh. 2,999

CO-ARINATE ADULT TABLETS 3'S

Product code: co--178411604720133

(0 reviews)

Available in stock

Co-Arinate Adult is an artemisinin-based combination therapy (200mg artesunate + 500mg sulfamethoxypyrazine + 25mg pyrimethamine) used to treat all forms of malaria, including multi-drug-resistant Plasmodium falciparum. Its 3-tablet regimen allows full treatment within 24 hours, improving convenience and adherence.

Ksh 545

What Is Co-Arinate Adult and What Is It Used For?

Co-Arinate Adult is a fixed-dose combination antimalarial for the curative treatment of uncomplicated malaria, including multidrug-resistant Plasmodium falciparum strains. Artesunate rapidly clears parasitaemia, while sulfamethoxypyrazine and pyrimethamine act synergistically as antifolate/sulfonamide partner drugs to prevent recrudescence.

Co-Arinate Adult is used as a curative treatment across all forms of malaria within a 48-hour treatment window, and is intended for adults and patients above the paediatric weight range covered by Co-Arinate Junior.

4. How to Take This Medicine

Dosing Schedule

One tablet immediately on diagnosis (approximately 4mg/kg artesunate for the standard adult weight range), one tablet 24 hours later, and one tablet a further 24 hours after that — three tablets total over 48 hours.

Critical Timing

A strict 24-hour interval must be maintained between each dose; taking doses too close together or too far apart reduces effectiveness and encourages resistance.

Higher Body Weight

Adults above 80kg may need dose adjustment — confirm with the prescriber.

5. Side Effects

Common Side Effects

     Nausea

     Vomiting

     Abdominal discomfort

     Dizziness

     Headache

Uncommon Side Effects

     Rash

     Itching (sulfonamide sensitivity)

Serious Side Effects — Seek Immediate Medical Attention

     Severe skin reactions (Stevens-Johnson syndrome), sulfonamide-related

     Haemolysis in G6PD-deficient individuals, dark urine, jaundice

     Blood dyscrasias with prolonged or repeated antifolate exposure

6. Contraindications

The following patients should NOT use this medication:

     Known hypersensitivity to sulfonamides, artesunate, or pyrimethamine

     G6PD deficiency (increased haemolysis risk)

     Severe hepatic or renal impairment

     First-trimester pregnancy: confirm current national malaria treatment guideline positioning with the prescriber

7. Safety Warnings and Special Precautions

     National Treatment Positioning: Kenya's national first-line treatment for uncomplicated malaria is Artemether-Lumefantrine (AL) per Ministry of Health/NMCP guidelines. Co-Arinate is generally used as an alternative ACT, for example where AL is unsuitable or unavailable.

     Strict Dosing Interval: The 24-hour spacing between doses is essential for efficacy — reinforce this explicitly with patients, as it is a common point of non-adherence.

     Confirm Diagnosis First: Confirm malaria diagnosis by RDT or microscopy before treatment; do not use presumptively, in line with antimalarial resistance stewardship.

8. Drug Interactions

     Other antifolate drugs (e.g. trimethoprim-sulfamethoxazole/co-trimoxazole, methotrexate): Additive bone marrow suppression risk — avoid concurrent use where possible.

     Other sulfonamide-based medicines: Cross-sensitivity risk — check allergy history carefully before dispensing.

9. Storage Instructions

     Store below 30°C, dry place, protected from moisture and direct sunlight.

     Keep out of reach of children.

10. Prescription Status in Kenya

Co-Arinate Adult is a Prescription Only Medicine (POM), dispensed against a confirmed malaria diagnosis in line with PPB and national malaria treatment guidelines.

11. Patient Guidance

💊 Key Points for Patients:

Take all three tablets exactly 24 hours apart — do not skip doses or take them closer together, even if you feel better after the first tablet.

Complete the full course.

Return promptly if symptoms worsen, or if you develop a rash, yellowing of the eyes/skin, or unusually dark urine.

Discuss with your doctor if you are pregnant before starting treatment.

12. Pharmacist / Prescriber Notes

Confirm parasitological diagnosis before dispensing — avoid presumptive treatment, consistent with antimalarial resistance stewardship.

Ask about known G6PD status where feasible, particularly in populations with higher G6PD deficiency prevalence.

Reinforce the strict 24-hour dosing interval, and flag to prescribers that this is a second-line/alternative ACT relative to AL under current Kenyan malaria treatment policy.

 

13. Frequently Asked Questions (FAQs)

Q1: Why is there a 24-hour gap between each tablet?

A: This spacing is essential to how the combination clears the parasite — taking doses too close together or too far apart reduces effectiveness.

Q2: Can I take this if I'm pregnant?

A: Discuss with your doctor — pregnancy requires specific antimalarial protocols, especially in the first trimester.

Q3: What if I vomit shortly after taking a dose?

A: Contact your pharmacist or doctor — a repeat dose may be needed depending on timing.

Q4: Is this the standard malaria treatment in Kenya?

A: Artemether-Lumefantrine is the standard first-line treatment; Co-Arinate is used as an alternative in specific situations.

Q5: Can I stop once I feel better?

A: No — complete all three doses on schedule to fully clear the infection and prevent recurrence or resistance.

There are no product reviews yet.


Related Products


Recently Viewed